ArticleDiabetology & metabolic syndrome2026
The predictive value of glycated albumin and hemoglobin A1c for all-cause and cardiovascular mortality in chronic kidney disease patients.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycated Albumin and Cardiovascular Mortality in CKD Stage V Patients with Diabetes Mellitus: A Five-Year Follow-Up Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe reliability of hemoglobin A1c (HbA1c) as a glycemic marker is limited in chronic kidney disease (CKD), which has led to increased interest in glycated albumin (GA). This study aimed to compare the associations of GA and HbA1c with mortality.
methodsThis prospective study used data from the National Health and Nutrition Examination Survey (1999-2004). Cox proportional hazards regression analysis with weight adjustment and restricted cubic spline regression were used to examine the associations between GA/HbA1c and mortality. The discriminative performance of GA and HbA1c for mortality was assessed via the concordance index (C-index), net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
resultsA total of 1,532 (62.97%) all-cause deaths and 473 (19.44%) cardiovascular (CV) deaths among the 2,433 participants with CKD occurred over a median of 12.46 years of follow-up. The associations between GA and all-cause mortality as well as CV mortality showed a positive linear pattern (P
conclusionsGA is more strongly associated with mortality than HbA1c in patients with CKD, particularly in the early stages, highlighting its potentially complementary value in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.